Reata Pharmaceuticals Inc (RETA.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2015||Chairman of the Board, President, Chief Executive Officer|
|47||2015||Chief Financial Officer and Vice President, Strategy|
|38||Chief Medical Officer and Vice President, Product Development|
|47||Vice President, Chief Development Officer|
|69||2015||Vice President, Chief Legal Officer|
- BRIEF-Reata Pharmaceuticals Posts Q1 Earnings Per Share $0.16
- BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone
- BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome
- BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan
- BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial